AXIM - AXIM files amended EUA for diagnostic test for COVID-19 neutralizing antibodies

AXIM Biotechnologies ([[AXIM]] -2.4%) has filed an amended Emergency Use Authorization ((EUA)) application with the FDA.AXIM first filed the EUA in September for measuring COVID-19 neutralizing antibodies in plasma and serum through its rapid diagnostic test. The Company amended the EUA to include positive results from a Biosafety Level 3 live virus test that positively correlates the rapid 10-minute lateral flow assay test to detect and measure levels of functional COVID-19 neutralizing antibodies.In August of this year, AXIM signed an exclusive limited licensing, manufacturing and distribution agreement with Empowered Diagnostics for high volume production of the Company’s ImmunoPass rapid diagnostic test.

For further details see:

AXIM files amended EUA for diagnostic test for COVID-19 neutralizing antibodies